Analysts have been eager to weigh in on the Healthcare sector with new ratings on DENTSPLY SIRONA (XRAY), Syndax Pharmaceuticals (SNDX) and Orchard Therapeutics (ORTX).
DENTSPLY SIRONA (XRAY)
In a report issued on May 8, Steven Valiquette from Barclays maintained a Hold rating on DENTSPLY SIRONA, with a price target of $40.00. The company’s shares closed last Friday at $40.65.
According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 4.0% and a 55.2% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Capital Senior Living, Molina Healthcare, and Community Health.
DENTSPLY SIRONA has an analyst consensus of Moderate Buy, with a price target consensus of $49.33, a 17.8% upside from current levels. In a report issued on April 24, H.C. Wainwright also maintained a Hold rating on the stock with a $38.00 price target.
See today’s analyst top recommended stocks >>
Syndax Pharmaceuticals (SNDX)
Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals on May 8 and set a price target of $25.00. The company’s shares closed last Friday at $18.03.
According to TipRanks.com, Lawson is a 5-star analyst with an average return of 8.9% and a 49.1% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Springworks Therapeutics, and Karyopharm Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syndax Pharmaceuticals with a $20.17 average price target, a 9.9% upside from current levels. In a report issued on April 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $19.00 price target.
Orchard Therapeutics (ORTX)
Barclays analyst Gena Wang maintained a Buy rating on Orchard Therapeutics on May 8 and set a price target of $15.00. The company’s shares closed last Friday at $10.50.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 19.8% and a 53.1% success rate. Wang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Orchard Therapeutics is a Strong Buy with an average price target of $22.25, a 100.5% upside from current levels. In a report issued on May 7, Wedbush also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
